Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials. VIENNA, June 19, 2023 /PRNewswire/ — Delta4, a pioneering digital drug discovery company specializing in identifying new therapeutic indications for drugs with established safety … Read more